Exalenz Bioscience creates cutting-edge diagnostic and monitoring platforms, which analyze minute changes in a patient’s exhaled breath. Specializing in noninvasive H. pylori and liver function diagnostics, our patented BreathID® technology delivers immediate results with industry leading specificity and sensitivity.

The BreathID® platform offers a user-friendly interface and a cost-effective clinical diagnostic solution that can be used in any clinical setting, including office-based practices, hospitals, laboratories and the ICU.

Driven by excellence as our core value, Exalenz Bioscience is committed to creating innovative diagnostics for management and monitoring of a broad range of GI and liver disorders. We make testing convenient for patients and simple to administer for healthcare professionals.

Quick Facts

Exalenz Bioscience provides Gastroenterologists, General Practice Physicians and Hepatologists advanced tools for diagnosing and managing a wide range of conditions.

More Facts

Financial report

Quarterly and annual reports for Exalenz (EXEN), traded on the Tel Aviv Stock Exchange (TASE).

More Reports


November 15, 2018
Exalenz Announces Third Quarter 2018 Financial Results

More News


UEF Week |  Booth #X5/12
October 22-24 2018, Vienna

More Events

contact us